BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis 2022:S1473-3099(22)00311-5. [PMID: 35803289 DOI: 10.1016/S1473-3099(22)00311-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Acosta N, Bautista MA, Waddell BJ, Du K, McCalder J, Pradhan P, Sedaghat N, Papparis C, Beaudet AB, Chen J, Van Doorn J, Xiang K, Chan L, Vivas L, Low K, Lu X, Lee J, Westlund P, Chekouo T, Dai X, Cabaj J, Bhatnagar S, Ruecker N, Achari G, Clark RG, Pearce C, Harrison JJ, Meddings J, Leal J, Ellison J, Missaghi B, Kanji JN, Larios O, Rennert-May E, Kim J, Hrudey SE, Lee BE, Pang X, Frankowski K, Conly J, Hubert CRJ, Parkins MD. Surveillance for SARS-CoV-2 and its variants in wastewater of tertiary care hospitals correlates with increasing case burden and outbreaks. J Med Virol 2022;95. [PMID: 36579780 DOI: 10.1002/jmv.28442] [Reference Citation Analysis]
2 Huo J, Dijokaite-Guraliuc A, Liu C, Zhou D, Ginn HM, Das R, Supasa P, Selvaraj M, Nutalai R, Tuekprakhon A, Duyvesteyn HME, Mentzer AJ, Skelly D, Ritter TG, Amini A, Bibi S, Adele S, Johnson SA, Paterson NG, Williams MA, Hall DR, Plowright M, Newman TAH, Hornsby H, de Silva TI, Temperton N, Klenerman P, Barnes E, Dunachie SJ, Pollard AJ, Lambe T, Goulder P, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR; OPTIC consortium, ISARIC4C consortium. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. Cell Rep 2023;42:111903. [PMID: 36586406 DOI: 10.1016/j.celrep.2022.111903] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Focosi D, Quiroga R, Mcconnell S, Johnson MC, Casadevall A. Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge. IJMS 2023;24:2264. [DOI: 10.3390/ijms24032264] [Reference Citation Analysis]
4 Lim K, Nishide G, Sajidah ES, Yamano T, Qiu Y, Yoshida T, Kobayashi A, Hazawa M, Ando T, Hanayama R, Wong RW. Nanoscopic Assessment of Anti-SARS-CoV-2 Spike Neutralizing Antibody Using High-Speed AFM. Nano Lett 2023;23:619-28. [PMID: 36641798 DOI: 10.1021/acs.nanolett.2c04270] [Reference Citation Analysis]
5 Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, Focosi D, Casadevall A, Joyner MJ. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Netw Open 2023;6:e2250647. [PMID: 36633846 DOI: 10.1001/jamanetworkopen.2022.50647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Franchini M, Casadevall A, Joyner MJ, Focosi D. WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients? Life (Basel) 2023;13. [PMID: 36676084 DOI: 10.3390/life13010134] [Reference Citation Analysis]
7 Focosi D, McConnell S, Shoham S, Casadevall A, Maggi F, Antonelli G. Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics. Int J Antimicrob Agents 2023;61:106708. [PMID: 36603694 DOI: 10.1016/j.ijantimicag.2022.106708] [Reference Citation Analysis]
8 Keppler-Hafkemeyer A, Greil C, Wratil PR, Shoumariyeh K, Stern M, Hafkemeyer A, Ashok D, Hollaus A, Lupoli G, Priller A, Bischof ML, Ihorst G, Engelhardt M, Marks R, Finke J, Bertrand H, Dächert C, Muenchhoff M, Badell I, Emmerich F, Halder H, Spaeth PM, Knolle PA, Protzer U, von Bergwelt-Baildon M, Duyster J, Hartmann TN, Moosmann A, Keppler OT. Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma. Nat Cancer 2023;4:81-95. [PMID: 36543907 DOI: 10.1038/s43018-022-00502-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Arora P, Kempf A, Nehlmeier I, Schulz SR, Jäck HM, Pöhlmann S, Hoffmann M. Omicron sublineage BQ.1.1 resistance to monoclonal antibodies. Lancet Infect Dis 2023;23:22-3. [PMID: 36410372 DOI: 10.1016/S1473-3099(22)00733-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 17.0] [Reference Citation Analysis]
10 Gachoud D, Bertelli C, Rufer N. Understanding the parameters guiding the best practice for treating B-cell-depleted patients with COVID-19 convalescent plasma therapy. Br J Haematol 2023;200:e25-7. [PMID: 36354067 DOI: 10.1111/bjh.18540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Baker D, Forte E, Pryce G, Kang AS, James LK, Giovannoni G, Schmierer K. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination. Mult Scler Relat Disord 2023;69:104425. [PMID: 36470168 DOI: 10.1016/j.msard.2022.104425] [Reference Citation Analysis]
12 Morgan MS, Yan K, Le TT, Johnston RA, Amarilla AA, Muller DA, McMillan CLD, Modhiran N, Watterson D, Potter JR, Sng JDJ, Lor M, Paramitha D, Isaacs A, Khromykh AA, Hall RA, Suhrbier A, Rawle DJ, Hobson-Peters J. Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern. Viruses 2022;15. [PMID: 36680179 DOI: 10.3390/v15010139] [Reference Citation Analysis]
13 Nevejan L, Ombelet S, Laenen L, Keyaerts E, Demuyser T, Seyler L, Soetens O, Van Nedervelde E, Naesens R, Geysels D, Verstrepen W, Cattoir L, Martens S, Michel C, Mathieu E, Reynders M, Evenepoel A, Hellemans J, Vanhee M, Magerman K, Maes J, Matheeussen V, Boogaerts H, Lagrou K, Cuypers L, André E. Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts. Viruses 2022;14. [PMID: 36560741 DOI: 10.3390/v14122736] [Reference Citation Analysis]
14 Focosi D, Quiroga R, Mcconnell SA, Johnson MC, Casadevall A. Convergent evolution in SARS-CoV-2 Spike creates a variant soup that causes new COVID-19 waves.. [DOI: 10.1101/2022.12.05.518843] [Reference Citation Analysis]
15 Zou J, Jing F. Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19. Pharmaceuticals (Basel) 2022;15. [PMID: 36558922 DOI: 10.3390/ph15121472] [Reference Citation Analysis]
16 Ling Z, Yi C, Sun X, Yang Z, Sun B. Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies. Sci China Life Sci 2022. [PMID: 36443513 DOI: 10.1007/s11427-022-2215-6] [Reference Citation Analysis]
17 Snell LB, Bakrania P, Williams TGS, Tam JCH, Fontoura DDS, Shaw E, Daunt A, Edgeworth JD, Hemsley CJ, Fields P, Agarwal S, Lams B, Cahill H, Milligan I, Botgros A, Nebbia G, Douthwaite ST, Aarons E. Severe COVID-19 caused by persistent SARS-CoV-2 infection successfully treated with dual direct acting antivirals.. [DOI: 10.21203/rs.3.rs-2227591/v1] [Reference Citation Analysis]
18 Sullivan DJ, Franchini M, Joyner MJ, Casadevall A, Focosi D. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. Nat Commun 2022;13:6478. [PMID: 36309490 DOI: 10.1038/s41467-022-33864-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
19 Focosi D, Franchini M. Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe. Life 2022;12:1704. [DOI: 10.3390/life12111704] [Reference Citation Analysis]
20 Fournelle D, Mostefai F, Brunet-ratnasingham E, Poujol R, Grenier J, Gálvez JH, Pagliuzza A, Levade I, Moreira S, Lapierre SG, Chomont N, Kaufmann DE, Craig M, Hussin JG. Intra-host viral populations of SARS-CoV-2 in immunosuppressed patients with hematologic cancers.. [DOI: 10.1101/2022.10.19.512884] [Reference Citation Analysis]
21 Rada M. Grubovic Rastvorceva, Sedula Useini, Milena Stevanovic, Ilir Demiri, Elena Petkovic, Massimo Franchini, Daniele Focosi. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients—An Open-Label Phase II Clinical Trial. Life (Basel) 2022;12:1565. [PMID: 36295001 DOI: 10.3390/life12101565] [Reference Citation Analysis]
22 Focosi D, Casadevall A. A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment. Viruses 2022;14:1999. [PMID: 36146805 DOI: 10.3390/v14091999] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Sullivan DJ, Franchini M, Joyner MJ, Casadevall A, Focosi D. Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma sources. medRxiv 2022:2021. [PMID: 35982681 DOI: 10.1101/2021.12.24.21268317] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
24 Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, Focosi D, Casadevall A, Joyner MJ. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review.. [DOI: 10.1101/2022.08.03.22278359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]